Allurion Technologies is implementing a 1-for-15 reverse stock split of its common stock to support its plan to regain listing on a national securities exchange such as the NYSE or NYSE American. The split becomes effective at 12:01 a.m. Eastern Time on June 18, 2026, after which every 15 issued or outstanding shares will be combined into one share without changing par value.
This will reduce the number of outstanding shares of common stock from approximately 15,006,253 to approximately 1,000,417, with fractional positions rounded up to the next whole share. The stock will trade on a split-adjusted basis on the OTCQB under the temporary symbol “ALURD” for about 20 trading days before reverting to “ALUR.”
All equity incentive awards, options, RSUs, convertible notes and warrants, including public warrants, will be proportionally adjusted. Each public warrant trading as “ALUR WS” will become exercisable for 0.00378787 shares of common stock at an exercise price of $3,037.50 per share, reflecting the 15-to-1 reverse split ratio.
Allurion Technologies, Inc. reported a change in its external auditor and reiterated previously disclosed weaknesses in its financial controls. The Audit Committee dismissed Deloitte & Touche LLP as independent registered public accounting firm effective May 22, 2026, after Deloitte had audited the company since 2016. Deloitte’s reports on the fiscal years ended December 31, 2024 and 2025 contained no adverse opinions or qualifications, and the company states there were no disagreements with Deloitte on accounting, disclosure, or audit scope.
The company did, however, report material weaknesses in internal control over financial reporting for 2024, 2025 and the interim period through May 22, 2026. These relate to insufficient segregation of duties in the close process, inadequate staffing with public company and technical accounting expertise, and insufficient information systems controls around access and change management. On May 20, 2026, the Audit Committee appointed CBIZ CPAs P.C. as the new independent registered public accounting firm for the fiscal year ending December 31, 2026.
Allurion Technologies reported a challenging first quarter of 2026. Revenue was $2.9 million, down from $5.6 million a year earlier, as sales declined across several geographies. The company posted a net loss of $6.1 million compared with a $1.5 million loss in the prior-year quarter, partly driven by a $4.1 million warrant inducement expense.
Cash and cash equivalents were $5.1 million as of March 31, 2026, while total assets were $14.0 million against total liabilities of $91.9 million, resulting in a stockholders’ deficit of $77.9 million. The balance sheet includes a $48.8 million Revenue Interest Financing liability and $28.6 million of RTW Convertible Notes, both carried at fair value.
Management discloses substantial doubt about Allurion’s ability to continue as a going concern within one year, citing recurring operating losses, negative operating cash flows, covenant noncompliance under its credit facilities, and the need for additional capital. Cost reductions from prior restructuring actions sharply lowered operating expenses, but they did not offset weaker revenue and financing-related fair value movements.
Allurion Technologies, Inc. describes its business as a metabolically focused weight loss platform built around the Allurion Program, which combines the swallowable Allurion Smart Capsule gastric balloon with an AI-powered Virtual Care Suite for remote monitoring and behavior change.
The company highlights more than 200,000 patients treated across over 50 countries and positions its program as complementary to GLP-1 drugs. It reports FDA PMA approval in the United States for the Allurion Gastric Balloon System for adults with obesity, enabling U.S. commercialization. Recent financing steps include a November 2025 private placement and a February 2026 warrant inducement that raised cash but added new warrants.
Allurion also discloses NYSE minimum market-capitalization non-compliance and ongoing appeals of delisting determinations, with its common stock now trading on the OTC market and plans to seek a higher-tier OTC listing. The company emphasizes a large obesity market opportunity, a broad patent and trademark portfolio, and a strategy focused on global expansion, U.S. launch, and a path to profitability.